Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results ... although – following the Capvaxive approval – the CDC's Advisory Committee on Immunisation Practices (ACIP) is ...

Many nursing home residents are refusing COVID shots this winter, though flu vaccine penetration has remained strong historically.

The Centers for Disease Control and Prevention (CDC) is scheduled to review ... Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 ...

The CDC’s Advisory Committee on Immunization ... and that age-targeted approach is central to MSD’s targeted pneumococcal vaccine strategy. It is also deploying its age-targeted serotype ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...

BANDAR SERI BEGAWAN: The Ministry of Health (MoH) has introduced the pneumococcal conjugate vaccine (PCV) into Brunei Darussalam’s Expanded Programme on Immunisation, effective FeB 1 as part of ...

After the introduction of pneumococcal conjugate vaccine (PCV)-7, emergence of non-PCV7 serotypes, especially 19A, is prominent worldwide, which also contributes to the increase in antimicrobial ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...